tradingkey.logo

Bluejay Diagnostics Inc

BJDX
查看详细走势图
0.706USD
-0.039-5.27%
收盘 12/24, 13:00美东报价延迟15分钟
1.16M总市值
亏损市盈率 TTM

Bluejay Diagnostics Inc

0.706
-0.039-5.27%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-5.27%

5天

-20.31%

1月

-48.83%

6月

-55.86%

今年开始到现在

-85.50%

1年

-81.42%

查看详细走势图

TradingKey Bluejay Diagnostics Inc股票评分

单位: USD 更新时间: 2025-12-24

操作建议

Bluejay Diagnostics Inc当前公司基本面数据相对非常健康,增长潜力较大。当前估值合理,在生物技术与医疗研究行业排名244/404位。机构持股占比非常高,中期看,股价处于下降通道。近一个月,市场表现非常差,但基本面评分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。

Bluejay Diagnostics Inc评分

相关信息

行业排名
244 / 404
全市场排名
518 / 4562
所属行业
生物技术与医疗研究

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 0 位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

Bluejay Diagnostics Inc亮点

亮点风险
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
利润高增长
公司净利润处于行业前列,最新年度总收入0.00美元
估值合理
公司最新PE估值-0.01,处于3年历史合理位
詹姆斯·西蒙斯持仓
明星投资者詹姆斯·西蒙斯持仓,最新持仓市值0.00

Bluejay Diagnostics Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

Bluejay Diagnostics Inc简介

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
公司代码BJDX
公司Bluejay Diagnostics Inc
CEODey (Neil)
网址https://bluejaydx.com/

常见问题

Bluejay Diagnostics Inc(BJDX)的当前股价是多少?

Bluejay Diagnostics Inc(BJDX)的当前股价是 0.706。

Bluejay Diagnostics Inc的股票代码是什么?

Bluejay Diagnostics Inc的股票代码是BJDX。

Bluejay Diagnostics Inc股票的52周最高点是多少?

Bluejay Diagnostics Inc股票的52周最高点是10.200。

Bluejay Diagnostics Inc股票的52周最低点是多少?

Bluejay Diagnostics Inc股票的52周最低点是0.712。

Bluejay Diagnostics Inc的市值是多少?

Bluejay Diagnostics Inc的市值是1.16M。

Bluejay Diagnostics Inc的净利润是多少?

Bluejay Diagnostics Inc的净利润为-34.16M。

现在Bluejay Diagnostics Inc(BJDX)的股票是买入、持有还是卖出?

根据分析师评级,Bluejay Diagnostics Inc(BJDX)的总体评级为--,目标价格为--。

Bluejay Diagnostics Inc(BJDX)股票的每股收益(EPS TTM)是多少

Bluejay Diagnostics Inc(BJDX)股票的每股收益(EPS TTM)是-99.673。
KeyAI